Phase 1 Study of BHT-3021 in Subjects With Type 1 Diabetes Mellitus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this study is to determine the safety of BHT-3021 injections given weekly for 12 weeks and to evaluate the effect of BHT-3021 on antibody and immune (T cell) responses to autoantigens (e.g. insulin). Changes in pancreatic beta cell function, insulin requirements and blood glucose levels will also be evaluated.
Epistemonikos ID: 76fe3a69cddf5fa716977728cd6abaa9d182c889
First added on: May 04, 2024